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ABSTRACT 
Background: Barrett’s esophagus (BE), caused by Gastroesophageal Reflux Disease (GERD), is 
the main premalignant condition for esophageal adenocarcinoma (EAC). The majority of BE and 
EAC patients are missed or diagnosed late resulting in dismal outcomes. Multiple studies have 
proposed serum microRNAs (miRNAs) as promising biomarkers for benign and malignant 
conditions. MicroRNAs contained in serum exosomes have increased stability and are a unique, 
non-invasive strategy for BE and EAC diagnosis. 
Methods: Serum from patients with GERD, BE and EAC (n=8 each) were differentially 
centrifuged to isolate exosomes. RNA was extracted with Trizol and next-generation sequencing 
was performed on the Illumina HiSeq2500 Sequencing platform. Analysis of the data was 
conducted using mirDeep2/EdgeR and prediction classification analysis. A False Discovery Rate 
(FDR) < 0.05 was considered significant. 
Results: All subjects were white males with the following mean ages: GERD: 58±9 years; BE: 
63±8 years; EAC: 64±3 years (p=0.3833). Comparison of serum exosomal miRNA profiles 
among the 3 groups found most significant differences between EAC patients compared to BE 
and GERD patients (79 and 85 miRNAs were found in EAC vs BE and GERD, respectively). 
Comparison of BE versus GERD patients found 17 differentially expressed serum exosomal 
miRNAs. Additionally, for each of the disease comparisons, approximately half of the significant 
miRNAs were up-regulated and the half were down-regulated. Prediction analysis identified a 
signature of 34 miRNAs that could be used to distinguish these conditions. 
Conclusion: We have identified promising candidate serum miRNAs for distinguishing GERD 
patients with and without BE and EAC. These findings need to be further validated to develop 
blood-based assays for clinical use.  
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BACKGROUND AND CLINICAL SIGNIFICANCE  
 The eponym “Barrett’s Esophagus (BE)” is named after Norman Rupert Barrett, a 
distinguished thoracic surgeon. Interestingly, however, the condition that bears his name was first 
described by a Boston pathologist named Wilder Tileston nearly a half a century before Barrett 
published a paper describing the disease. In 1950, Barrett characterized BE in an article titled 
“Chronic peptic ulcer of the oesophagus and oesophagitis” but his suggested mechanism has since 
been proven to be incorrect [1]. He proposed that a congenitally short esophagus led to extension 
of the stomach into the mediastinum and thus could explain the tendency of esophageal ulcers to 
be surrounded by gastric type mucosa [2]. Earlier, in 1906, Tileston, had described how the mucosa 
surrounding esophageal ulcers bore resemblance to the mucosa of the stomach. In the same paper, 
he proposed a mechanism that is widely accepted today as the pathogenesis of Barrett’s 
Esophagus; Tileston wrote, “The first requisite for the formation of the peptic ulcer of the 
oesophagus is an insufficiency of the cardia.”  In other words, gastric contents were not being 
contained within the stomach, which is essentially what physicians diagnose as Gastroesophageal 
Reflux Disease (GERD) today.  
 The estimated prevalence of GERD in the United States is 20%, which equates to 
approximately 10 million people [3, 4]. The prevailing hypothesis is that residual cells at the 
gastroesophageal junction migrate proximal during acid-induced injury leading to abnormal 
placement of those cells [5, 6]. Subsequently, the normal squamous epithelium is replaced by the 
columnar epithelium [7-9]. The resulting condition is termed Barrett’s esophagus (BE), an 
epithelial metaplasia from squamous to columnar. BE is important because it is the primary 
premalignant condition for esophageal adenocarcinoma (EAC). In patients with chronic GERD, 
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the prevalence of BE is 10–15 % [10]. The progression of BE to EAC involves histological changes 
that result from sequential accumulation of genetic and epigenetic changes: non-dysplastic 
Barrett’s metaplasia, low-grade dysplasia, high-grade dysplasia, and ultimately, adenocarcinoma.  
 The US incidence of esophageal adenocarcinoma has risen faster than any other 
malignancy in recent years, its incidence makes it the most rapidly increasing cancer in the United 
States[11]. Unfortunately, it is also highly lethal with a dismal 5-year survival rate of less than 
15% [12]. Although the absolute annual risk of Barrett’s patients developing adenocarcinoma is 
lower than previously thought (0.12-0.3%), the cumulative lifetime risk in patients with BE has 
been estimated to be 7-14% [13, 14]. Moreover, the risk of developing esophageal cancer is 50-
100 times more likely in those patients with BE compared to the general population (standardized 
incidence ratio of 11.3) [13].  
Smoking, diet, abdominal obesity, age >50 and hiatal hernia have all been implicated as 
risk factors for GERD.  Obesity is an important modifiable risk factor and is associated with 
increased risks for complications such as BE and EAC [15, 16]. The rising prevalence of EAC as 
well as its major risk factor obesity is worrisome. Over the past 35 years, obesity rates have more 
than doubled with more than one-third of U.S. adults currently considered obese [17]. Age is also 
important risk factor for EAC, leading to another cause for concern is the increase in the aging 
population. Americans ages 65 and older make up 13% of the US population. By 2030, when all 
the baby boomers will have passed age 65, the over-65 persons will reach 20% of the population 
[18]. The increasing prevalence of the aging population and the association of obesity with these 
conditions contribute to the daunting cumulative effect they have on EAC rates and related 
public health and healthcare spending [19]. 
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Diagnosis of Barrett’s esophagus 
According to the recommendations by the American Gastrointestinal Association (AGA), 
patients with multiple risk factors for BE, such as white race, chronic GERD and age >50 should 
be screened by esophagogastroduodenoscopy (EGD). The two main criteria proposed by the AGA 
to define BE are, a) columnar lined esophagus based on the appearance of “salmon” colored distal 
esophageal mucosa and b) biopsies that demonstrate the presence of intestinal metaplasia by 
detection of goblet cells, a specialized columnar epithelium that bears resemblance to the intestinal 
mucosa. This latter requirement is limited to the United States [4]. The European definition simply 
requires the presence of endoscopically visible columnar lined esophagus that on biopsies could 
either have gastric-type or intestinal-type epithelium. Once BE is identified, the patients are 
entered into a program of surveillance endoscopies to detect dysplasia and EAC [16]. Under this 
program, biopsies are obtained every 1-2 cm along the length of BE for histologic evaluation of 
dysplasia and EAC. To standardize the description of BE, the Prague Classification system of 
circumferential (C) and maximal length (M) has been widely accepted [20, 21]. On endoscopy, the 
gastroesophageal junction is identified and the absolute distance of circumferential and proximal 
columnar lining from this point is noted. If BE was circumferential for 2 cm above this junction, 
for example, and the maximal extent of non-circumferential BE (including the tongues) was 5cm 
above this junction, the BE in this situation would be Prague classification: C2M5 (Figure 1). BE 
lengths can vary from 1 cm to 20 cm depending on the patient. Currently, patients undergoing 
surveillance receive an endoscopy every 3–5 years for BE without dysplasia, every 6-12 months 
for low-grade dysplasia, and every 3 months for high-grade dysplasia.  
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 It is widely accepted that there are some significant problems with the current practice of 
BE screening and surveillance. As mentioned above, there are millions of individuals with GERD 
at risk for BE and, therefore at risk for EAC. However, it is expensive and impractical for the 10 
million adults with GERD to go through an invasive upper endoscopy, the current gold standard 
for BE screening [4]. Also, periodic surveillance endoscopies are not cost-effective. There are 
other problems such as sampling error of biopsies and substantial intra-observer and inter-observer 
(κ= 0.30) variability in the diagnosis of dysplasia among pathologists [22-24].  
Figure 1. A) Depiction of Barrett's esophagus (dark red) with a Prague classification C2M5. 
Gastroenterology. 2006 Nov; 131(5):1392-9. Epub 2006 Aug 16. B.) Barrett’s esophagus (salmon 
colored columnar mucosa) and normal, non-diseased esophagus (whitish squamous mucosa) on 
endoscopy. C.) Advanced Barrett’s esophagus.  The open circle marks a nodule, a sign of early 
cancer. 
A. 
B. C. 
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 Two major problems that form the basis of the current proposal are that the majority of 
BE remains undiagnosed and that greater than 80% of EACs are diagnosed late without a prior 
diagnosis of BE [25]. Although this raises the question of whether EAC arises de novo from a 
pathway alternate to BE, data suggests that this is unlikely to be the case. In greater than 90% of 
patients with EAC, the BE mucosa becomes visible again once the cancerous tissue sloughs away 
with chemoradiation [26]. This indicates that the cancer had overgrown the BE epithelium making 
it invisible.  Thirty percent of patients with BE do not experience reflux symptoms and therefore 
may remain unscreened [7]. These data suggest the screening eligibility criteria are limited in 
predicting those with BE and therefore leads to a large number of patients with BE undiagnosed 
in the population [25].  
 This lack of timely diagnosis of BE is a missed opportunity for early diagnosis of EAC.  
The majority of patients wait until symptoms such as dysphagia develop and present with an 
advanced-stage esophageal cancer instead of an earlier stage when treatment options are possible. 
Early diagnosis could impact survival as effective endoscopic therapy for BE dysplasia and cancer 
is now available. Intervention in the premalignant stage of EAC may save the lives of patients who 
develop incurable EAC each year. Thus, there is a need for an alternative, simple, less invasive 
and more effective diagnostic tool to screen GERD patients for BE and to identify those patients 
with BE that have cancer.  
 Due to the above limitations, recently there has been much interest in non-endoscopic 
detection methods for timely diagnosis of BE with the goal of preventing esophageal 
adenocarcinoma (EAC) [27-30].   
Exosomes and MicroRNA 
 One emerging strategy is the use of exosomal contents as a diagnostic biomarker. 
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Exosomes are approximately 40-100 nm membrane-bound vesicles that are secreted from nearly 
all cell types. Exosomes are ubiquitous in various body fluids such as serum, saliva, breast milk, 
ovarian follicular fluid and urine [31-35]. Their contents are thought to play a crucial role in 
cellular communication and reflect properties of the body’s benign or disease state. Exosomes are 
produced when the membrane of parental cells buds inwardly to form an endosome, then 
subsequent inward budding of the endosome membrane forms intraluminal vesicles (Figure 2).  
 
Figure 2. Schematic overview of MicroRNA and Exosome Biogenesis. RBP: RNA Binding 
Protein such as Argonaute and Nucleophosmin 
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This allows for lipids, cytokines, proteins and RNA to be incorporated in the vesicles [36]. Once 
this occurs the structure is called a multivesicular body (MVB). Some MVBs become degraded in 
lysosomes while others fuse to the plasma membrane and release the vesicles into the extracellular 
space.  
 Exosomes have proven to be stable in various conditions including the extracellular 
environment; because of this they are able to protect their cargo from being denatured or degraded 
[37-40].  Once exosomes are released into the extracellular space recipient cells can uptake the 
cargo. This results in a “message in a bottle" mechanism allowing distant cells to communicate 
and regulate the cellular processes of recipient cells [41, 42].  
 In order to catalog the identified contents of extracellular vesicles, the ExoCarta 
(http://www.exocarta.org) database was developed [43].  Recent data suggest that miRNAs can be 
found in exosomes [44]. MicroRNAs (miRNAs) are small (18–25 nucleotides long), endogenous, 
non-coding RNAs [26]. They have been found in plants, animals, and viruses. Specifically in 
humans, mature miRNAs function as regulatory molecules in a wide variety of fundamental 
cellular processes, such as proliferation, death, differentiation, motility, and invasiveness [27]. 
MicroRNA are being discovered and validated often and they currently they constitute 2-5% of 
the human transcriptome, equating to approximately 2,000 miRNA. Pri-miRNAs, are the initial 
transcripts resulting from RNAPol-II activity. Once pri-miRNA fold to form hairpins, they are 
processed into pre-miRNA, which are 60 to 100 nucleotides in length. Exportin exports pre-
miRNA from the nucleus to the cytoplasm where they are typically cleaved by the endonuclease 
Dicer; this results in a miRNA-miRNA* complex. Sometimes pre-miRNA can bypass Dicer and 
be released into the extracellular space contained in a microvesicle or exosome. For those that do 
not go this route, one strand, generally the miRNA strand, is designated to become a mature 
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miRNA and the other, most often the miRNA* strand, becomes degraded. In the cytoplasm the 
mature miRNA strand can bind with the RNA-induced silencing complex (RISC); this complex 
can then bind to specific target mRNA or get released in the extracellular space.  
 Depending on the degree of complementarity, miRNA binding can either block 
translation or promote mRNA degradation. MicroRNAs are predicted to regulate as much as 30% 
of all gene expression and have been intensively studied in cancer research [45]. A single miRNA 
can influence the expression of numerous genes transcripts and, thereby, may affect the physiology 
of a cell. Higher levels of a specific miRNA can lead to down regulation of key genes and, 
similarly, lower levels may lead to up-regulation of other key genes. They can give insight on the 
state of the body’s condition and have shown promise as specific tissue and serum biomarkers in 
multiple premalignant and malignant conditions [46-49]. Multiple studies have shown them to be 
good clinical markers for detection of cancerous and benign disease states [50-52]. In a previous 
study, miRNA profiles were found to mirror the developmental lineage and differentiation state of 
the tumors more accurately than mRNA[48].  
 A blood-based diagnostic test for BE and EAC would be a significant advancement, one 
that is capable of changing patient outcomes.  To date, no useful exosomal miRNAs have been 
used to diagnosis or distinguish GERD, BE or EAC from another. In this study, we sought a novel 
approach towards addressing the limitations of current diagnostic methods for these conditions in 
their population based applicability. Here, we isolated serum exosomes and preformed 
comprehensive miRNA profiling by next generation sequencing to identify a unique miRNA 
signature that is able to distinguish GERD, BE and EAC from each other.  
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METHODS 
Study Population and Tissue Sample Collection 
The patients for the current study were selected from an ongoing repository of controls 
and patients with GERD, BE and cancer. Frozen patient sera were randomly selected from this 
biorepository to include 8 patients each with GERD, BE and cancer. The creation of the 
repository and the use of specimens for this study was approved by the Institutional Review 
board at the Veterans Administration Medical Center Kansas City, Missouri. Specimens were 
obtained voluntarily after written informed consent. Adult patients (>18 years old) were enrolled 
and subjects with the following conditions were excluded: chronic liver disease, diagnosis of 
cancer in the last 3 years, an inability to discontinue the use of blood thinners, severe 
uncontrolled coagulopathy, history of unresolved drug or alcohol dependency, and prior history 
of esophageal or gastric surgery were excluded from the repository.  
All participants completed a validated GERD questionnaire. Patients who answered 
affirmative to the presence of GERD symptoms (heartburn, regurgitation, etc.) were defined to 
have GERD. After endoscopic examination, patients with a GERD were sub-classified based on 
evidence of mucosal injury; those with non-erosive reflux disease (NERD) and the others with 
erosive esophagitis (EE).  For this initial study, only those GERD patients who had erosive 
esophagitis (EE) were included because presence of erosive esophagitis definitively diagnoses 
GERD. Biopsies were obtained according to a standard protocol. Biopsied sections were 
reviewed by an experienced gastrointestinal pathologist for intestinal metaplasia, dysplasia and 
cancer  according to the criteria described by Montgomery et al.[53]. Biopsies are graded and if 
there is concern for high-grade dysplasia and/or cancer, the biopsies are reviewed by a second 
pathologist. BE was defined as presence of columnar lined esophagus at least 1 cm in length on 
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endoscopy with demonstration of intestinal metaplasia based on the presence of goblet cells in 
biopsies. For this study, the BE group included only those BE patients that did not have dysplasia 
to minimize the impact of dysplasia grade on miRNA expression.  
Isolation of exosomes  
Blood was collected in red-topped tubes and centrifuged at 3000 rpm for 10 minutes at 
the Veterans Administration Medical Center Kansas City, Missouri. The serum was then 
aspirated and stored at -80°C. Randomly selected sera were thawed and differentially ultra-
centrifuged to isolate exosomes. Following thawing serum was centrifuged at 2000 g for 20  min 
at 4°C and the resulting supernatant was centrifuged at 12 000 g for 45min. The supernatant was 
then transferred to a new tube and was ultra-centrifuged at 100 000 g for 120 min at 4 °C to pellet 
exosomes and microvesicles. The extracellular vesicle pellet that formed was re-suspended in 
4 mL of PBS and centrifuged for a final wash at 100 000 g for 90 min at 4 °C. After this, the 
supernatant was discarded and the remaining pellet was re-suspended in 100µL of PBS.  
Characterization of exosomes: Transmission Electron Microscope 
A 1:1 mix of exosomes in PBS to 2% glutaraldehyde was vortexed and 30 µL was placed 
on a spot dish.  Carbon-coated copper grids were glow-discharged in order to make them more 
hydrophilic. Next, a treated grid was floated on the drop for 20 minutes. The grid was then 
removed and allowed to float on 6 serial wells filled with deionized distilled water for rinsing. 
The grid was placed onto a drop of 1% uranyl acetate for ~10 s, excess liquid was drained by 
touching the edge of the grid against a piece of clean filter paper. The grid was allowed to dry for 
several minutes and then examined using a JEM-1200 EX microscope (JEOL, Akishima, Japan). 
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Exosomal RNA extraction   
Total RNA was extracted using TRIzol as per the manufacturer’s protocol (Ambion, 
Austin, TX). Briefly, 100µL of chloroform was added to 500µL of TRIzol and the resuspended 
pellet. After this, it was mixed vigorously and allowed to incubate at room temperature. The mix 
was centrifuged for 15 minutes at 4 degrees. The upper clear phase was transferred to a fresh 
tube and glycogen (1µL) and isopropanol (250µL) were added to precipitate the RNA. This was 
followed by vigorous mixing and centrifugation. The supernatant was carefully decanted and the 
remaining pellet was washed in 75% ethanol. After removing the ethanol, the RNA pellet was re-
suspended in DEPC-treated and nuclease free water. RNA quality was evaluated on Agilent 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).   
Next-Generation Sequencing 
Next-generation sequencing was performed to obtain a complete profile of exosomal 
miRNA from each patient. MicroRNA sequencing was performed using the Illumina HiSeq2500 
Sequencing System at the University of Kansas Medical Center – Genomics Core. TruSeq Small 
RNA library preparation protocol (Illumina, San Diego, CA) was used to generate libraries from 
EAC (n=8), GERD (n=8), and BE (n=8) patients. The exosomal RNA was ligated with 3’ and 5’ 
RNA adapters followed by a duplicated reverse transcription reaction and 15 cycle PCR 
amplification. The cDNA library was purified and size selected by using 3% marker F gel 
cassettes on the Pippin Prep Size Fractionation System (Sage Science, Beverly, MA). The 
Agilent 2100 Bioanalyzer was again used to validate the purified libraries and were quantified 
with the Roche LightCycler96 Real Time PCR System using FastStart Essential DNA Green 
Master (Roche Diagnostics, Basel). Following quantification by Cq values, libraries were 
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adjusted to the same concentration and pooled for multiplexed sequencing. Twelve random 
samples per lane were multiplexed resulting in two lanes for all of the 24 samples. 
Libraries were denatured, diluted and clustered onto the sequencing flow cell using the 
Illumina TruSeq Rapid Single Read (SR) Cluster Kit-HS. The clustered flow cell was sequenced 
using the Rapid Read mode with a 1x50 cycle read and index read. Sequence data was converted 
from .bcl file format to FASTQ files and de-multiplexed into individual sequences for further 
downstream analysis. 
MicroRNA signature for GERD, BE, and EAC 
To identify previously reported miRNAs present in our samples, the miRDeep2 software 
package was used [54]. The following steps were executed sequentially:  Sequences with more 
than one mismatch read or ones that contain characters other than A, C, G, T, U, and N were 
discarded. Adapter sequences were trimmed from the primary reads and sequences were mapped 
to the human reference genome, hg19 UCSC. Further, only sequences with at least 18 
nucleotides, after adapter removal, are retained and duplicate sequencing alignment reads are 
removed. miRDeep2 then tabulated the number of reads that aligned to the reference genome. 
Raw reads counts for each miRNA were normalized to the total number of miRNA reads in each 
sample.  
Differential pairwise exosomal microRNA analysis was performed using the EdgeR 
package from Bioconductor [55]. EdgeR uses a generalized linear model to assess differential 
expression between groups assuming the negative binomial distribution.  As over-dispersion may 
differ across genes with the dispersion parameter difficult to estimate per feature / tag, moderated 
estimates of the dispersion parameter from EdgeR were used. The obtained read counts for the 
13 
 
2,946 identified miRNA were first filtered based on a minimum requirement of >5 counts in at 
least 8 of the 24 patients; this yielded 353 miRNAs. Next, the counts were normalized by scaling 
for library size factors in order to deal with variation among samples. The normalized counts of 
the 353 miRNAs were considered for the pairwise comparisons. The results were adjusted for 
multiple testing using the Benjamini and Hochberg method. A False discovery rate (FDR) of 5% 
was considered significant [56]. 
In order to retrieve insight into diagnosis group variation, development of a classification 
signature was developed using Prediction Analysis for Microarrays (PAM) [57]. The PAM 
statistical method identifies the subsets of miRNA that best characterize each class by using the 
nearest shrunken centroid method. We used PAM to determine which miRNA are the most 
predictive of GERD, BE, and EAC based on their miRNA expression patterns. The analysis was 
done by randomly splitting the data set into training (21 samples) and test groups (3 samples). 
The shrinkage parameter or threshold was chosen by minimizing the prediction error using 7-
fold cross-validation within the training set. Choosing a larger threshold value would yield a 
smaller number of genes to include in the signature; thus making it more practical for clinical 
settings. The threshold value that returned the lowest classification error with the fewest yet 
strongest genes was estimated to be 2.0. 
Pathway Analysis 
Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood City, CA) was used to determine 
potential pathways involving the differential miRNAs and their suspected target gene transcripts. 
IPA provides insight into the interaction of these miRNAs and potential target genes in the 
disease process of GERD, BE and EAC. Differentially expressed miRNAs (FDR<0.05) from the 
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pairwise comparisons were imported into the “Core Analysis” module of IPA. Confidence levels 
were set to “highly predicted” and “experimental observed,” based on the Ingenuity Knowledge 
Base. Enriched networks from identified miRNA targets were reported after analysis. IPA ranks 
networks according their significance based on Fisher Exact test p-value (p-score = (-log10[P 
value])).  
Statistical Analysis 
Statistical analysis was performed using the SAS software package (SAS Institute Inc., 
2013). For categorical variables, the data were expressed as N (%) and continuous variables, the 
data were expressed as means (standard deviation).  The relationships among demographic and 
clinical factors were analyzed using the following tests: Kruskal-Wallis test was used to examine 
the differences between continuous demographic information in all three groups; Wilcoxon 
Mann-Whitney was performed to compare the differences between mean BE length for patients 
with BE and EAC; and Fishers exact was used for categorical data to evaluate the correlation 
between disease status and patient demographics. Differences were considered statistically 
significant at the level of P<0.05. 
RESULTS 
Patient Demographics and Clinical Characteristics  
All patients for this study were white males reflecting the underlying demographic 
predisposition of this disease and our attempts to evaluate homogeneous populations. The 
demographic information and the clinical characteristics of the subjects included in this study are 
summarized in Table 1. The average BMI of patients with esophageal adenocarcinoma was 
higher than those of patients with GERD (34.4± 11.92 versus 27.0± 5.34) but the difference was 
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not statistically significant (p = 0.3833). Over 63% of the patients in all three groups had a 
history of smoking but approximately one-third of participants in each patient group currently 
smoked. Similarly, greater than 63% of patients had a hiatal hernia present on endoscopic 
examination. K-Wallis Test did not confirm a significant difference in age or mean hernia length 
among the three patient groups. The mean lengths of columnar lined esophagus in patients with 
BE and EAC were C3.5M5.5 and C4.3M5.9 respectively, (p = 0.7251, Table 1). EAC patients 
were less likely to report GERD symptoms compared to the other two groups (p = 0.021).   
 
  
16 
 
Table 1.  Patient Characteristics and Clinical Parameters 
  
GERD 
Cases 
n= 8 
  
BE Cases 
n= 8 
  
EAC Cases 
n= 8 
  
Characteristics           P value 
              
AGE        
Mean (SD) 64.4 (10.2)  58.8 (12.7)  64.1 (10.2) 0.3833 
       
              
BMI        
Mean (SD) 27.02 (5.34)  32.03 (5.90)  34.37 (11.92) 0.3826 
       
              
SMOKING       
Current Smoker 3 (38%)  3 (38%)  2 (29%) 1.00 
Past Smoker 5 (63%)  6 (75%)  5 (71%) 1.00 
       
              
HIATAL HERNIA 5 (63%)  7 (88%)  7 (88%) 0.5573 
Mean Length of Hernia in cm 
(SD) 
4.8 (2.2)  3.4 (1.9)  3.3 (1.4) 0.4834 
       
              
GERD SYMPTOMS 7 (88%)  8 (100%)  3 (38%) 0.0206 
       
              
FAMILY HISTORY       
GERD 1 (13%)  3(38%)  6 (75%) 0.5573 
BE 0  0  1 (13%) 1.00 
EAC 0  0  1 (13%) 1.00 
       
              
MEDICATION USE       
PPI 7 (88%)  8 (100%)  8 (100%) 1.00 
Aspirin 5 (63%)  3(38%)  3 (38%) 1.00 
       
              
PRESENCE of BE   8 (100%)  8 (100%) 0.001 
Mean BE Length (SD) -  5.5 (3.7)  5.9 (3.2) 0.7251 
Mean Prague Classification -  C3.5M5.5  C4.3M5.9 - 
       
              
Pathological Stage       
I -  -  4 (50%) - 
II -  -  1 (13%) - 
III -  -  1 (13%) - 
IV -  -  2 (25%) - 
Values reported as N(%) unless otherwise noted. GERD, gastroesophageal reflux disease; BE, Barrett's 
esophagus; EAC, Esophageal adenocarcinoma 
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Exosome characterization  
 
After isolation, presence of exosomes was confirmed by transmission electron 
microscopy (TEM). TEM demonstrated numerous characteristic, cup-shaped, 30-100nm vesicles 
(Figure 3).  Figure 3 is representative of exosome preparations using the differential 
centrifugation technique described under methods. 
 
Next-generation sequencing alignment and analysis 
 
Next-generation sequencing (NGS), generated 11.8 million reads per sample. Low 
quality scores for sequenced samples can lead to a large number of false positive variant 
alignments. However, for the samples in this study, 97.8% of bases had a quality score greater 
than 30. This is equivalent to the probability of an incorrect base call 1 in 1000 times or a base 
call accuracy of 99.9% [58].  After processing and filtering with MirDeep2, an average of 2.4 
million reads per sample mapped to mature and validated miRNA sequences annotated in hg19 
UCSC (average: 25%, range: 8%-42%). Additionally, MiRDeep2 predicted more than 1,700 
novel microRNA unannotated sequences in serum exosomes.  
 
Figure 3. Transmission Electron Microscopy of negatively 
stained exosomes 
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To get a general idea about the serum exosomal miRNA diversity for each condition, 
Venn-diagrams were generated with each circle depicting the number of unique miRNA found in 
serum for each patient group and the overlap indicating the number of common miRNA. Patients 
with GERD had the greatest miRNA diversity in their serum miRNA with 73 miRNA being 
unique to its condition (Figure 4a). Notably, there was substantial overlap in unique miRNA 
when the Venn-diagram inclusion criteria was changed from a read count >1 to a read count 
>100; neither BE or EAC had unique miRNA under this condition. However, the serum miRNA 
in patients with GERD still exhibited the highest number of unique miRNA (Figure 5b).    
 
 
 
These results are consistent with the clinical observations that GERD patients have two distinct 
profiles with respect to complications. Some GERD patients are predisposed to BE and EAC 
whereas others will not develop BE and EAC despite continued GERD.  
Next, the serum exosomal miRNA profiles of GERD, BE and EAC were compared using 
EdgeR. The most significant differences were found when EAC patients were compared to BE 
A. 
B. 
Figure 4. Venn-diagram of miRNA found in serum exosomes for each patient population. 
(A) Number of miRNA present in all eight patients for each group (read>1). (B) Number 
of miRNA present with at least 100 raw counts in all eight patients for each group 
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and GERD patients; 79 and 85 differentially abundant miRNAs in EAC versus BE and EAC 
versus GERD respectively (Table 2). In comparison, 17 serum exosomal miRNAs were different 
when comparing BE vs. GERD patients. For each comparison, approximately half of the 
differentially expressed miRNAs were up-regulated and the other half were down-regulated 
(Table 2). Figure 5a, b and c show volcano plots of statistical significance against fold-change 
between disease states (the axes are hard to read).  A volcano plot of GERD vs EAC and BE vs 
EAC show seven miRNAs (Figure 5b) and 42 miRNAs (Figure 5a) with a FDR <0.05, 
respectively (red points). GERD patients, when compared to those with BE, had no miRNA with 
a FDR <0.05. Tables with a complete list significant genes for each pair wise comparison and 
fold change can be found in Appendix A, B and C.  
Using unsupervised hierarchical clustering a heat map was generated with significantly 
different miRNA (FDR< 0.05) from the pairwise EdgeR analysis. We found that 4 discrete 
clusters of serum exosomal miRNAs can differentiate patients with Barrett’s esophagus from 
patients with esophageal adenocarcinoma (Appendix D).  
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Figure 5. Volcano Plots of Pairwise comparisons and summary table. The x-axis shows the log2 fold-change 
in circulating miRNAs' expression between (A) BE vs EAC (B) GERD vs EAC and (C)GERD vs BE .The y-
axis shows the −log10 of the P value for each miRNA. The volcano plots show a visual representing of the 
strength of the association and magnitude of fold change. The blue line indicates comparisons with P < 0.01). 
The two vertical lines (red) are the fold change boundaries. MicroRNA with an FDR <0.05 are seen as red 
points on the plots.  
A. 
B. 
C. 
21 
 
 
  Increased Decreased Total 
GERD vs BE 9 8 17 
GERD vs EAC 40 39 79 
BE vs EAC 39 46 85 
n= 8 , P value<0.05   
 
Prediction Analysis for Microarrays (PAM) 
We used Prediction Analysis for Microarrays to generate a miRNAs list under optimal 
classification capabilities (threshold of 2.0) to distinguish between the three disease states 
(Figure 6). Seven-fold cross-validation yielded a 34 miRNA signature showing the greatest 
potential for distinguishing GERD, BE and EAC (Figure 7) with an overall misclassification rate 
of 0.36. The PAM model was able to accurately classify 64% of patients to the appropriate group 
(Figure 7b).  
A great deal of the miRNA in the PAM signature correlated with the differentially 
expressed miRNA from the pairwise comparisons. Interestingly, 21 out of the 42 miRNA 
considered significant (FDR<0.05) from the EdgeR analysis were found in the PAM miRNA 
classifiers. This is a 62% concordance from the two analysis techniques.  Figure 8 shows the heat 
map obtained using the miRNA gene signature of 34 genes. There were similar miRNA clusters 
that noticeably distinguished BE and EAC from those determined by the EdgeR analysis. The 
Table 2. Number of differentially abundant miRNA for each comparison. 
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miRNA clusters failed to distinguish the GERD population from others. Following the generated 
PAM signature, box plots were produced for the 34 miRNAs (Figure 9).  
 
 
 
Figure 6. Prediction Analysis for Microarrays miRNA signature. Plot depicts the shrunken centroids 
(expression level) for a threshold of 2.0 with the ranked list of significant miRNAs. Bars facing left 
represent negative shrunken centroid scores indicating decreased expression and the opposite is true 
for the bars facing right. 
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A. 
B. 
Figure 7. A) Misclassification error (predictive power) over various thresholds.  The upper panel shows 
misclassification error on the y axis. The labels across the top axis gives the potential number of miRNAs 
used in the classification; from the total number of miRNA in the entire set to a single one (far left to 
right). The lower panel shows the misclassification error for each diagnosis, with BE cases in red, EAC 
in green and GERD in blue. B) Cross-validation errors of the classifying miRNA. The X-axis represents 
the patient sample number and the Y-axis represents the Test Set probability of diagnosis. The 10X cross-
validation probabilities of a given sample belonging to each patient clinical phenotype are indicated by 
the various color on the graph. BE cases are in red, EAC in green and GERD in blue. The sum of 
probabilities for a given sample should equal 100%. 
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Figure 8. Heat map. Columns represent patient samples and rows represent the significant 
genes from PAM analysis. Scale bar indicates expression signal where yellow denotes genes 
with relative increased expression while blue denotes genes with relative decreased expression. 
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Figure 9. Distribution of miRNA abundance. Box plot of normalized counts for PAM signature miRNAs. 
1 of 3 
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Figure 9. Distribution of miRNA abundance. Box plot of normalized counts for PAM signature 
miRNAs. 2 of 3 
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Ingenuity Pathway analysis 
To assess whether certain regulatory networks were enriched in the three conditions, we 
performed a series of investigations using IPA. Comprehensive network analysis of the pairwise 
comparison data showed correlations with top networks relevant to the development of cancer 
(Table 3). The differentially enriched miRNA gene targets constituted about 40% of the 
molecules involved in cancer and inflammatory-associated networks.  Similarly, the diseases and 
Figure 9. Distribution of miRNA abundance. Box plot of normalized counts for PAM signature miRNAs. 
3 of 3 
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function analyses showed analogous biological processes impacted by these miRNA such as 
inflammatory disease and response, cancer, and organismal injury (Appendix E).  
  
Table 3. IPA Network summary for each pairwise comparison 
(A) GERD vs BE    
ID Top Diseases and Functions 
Focus 
Molecules 
Score 
1 
Skeletal and Muscular Disorders, Developmental 
Disorder, Hereditary Disorder 9 24 
    
(B) GERD vs EAC   
ID Top Diseases and Functions 
Focus 
Molecules 
Score 
1 Cancer, Organismal Injury and Abnormalities, 
Reproductive System Disease 25 66 
2 Connective Tissue Disorders, Inflammatory Disease, 
Inflammatory Response 23 57 
3 Infectious Disease, Organismal Development, 
Hematological Disease 1 3 
4 Cell Cycle, Cellular Movement, Cancer 1 2 
    
(C) BE vs EAC   
ID Top Diseases and Functions 
Focus 
Molecules 
Score 
1 Developmental Disorder, Hereditary Disorder, 
Skeletal and Muscular Disorders 20 43 
2 Cancer, Organismal Injury and Abnormalities, 
Reproductive System Disease 19 41 
3 Cancer, Organismal Injury and Abnormalities, 
Reproductive System Disease 10 22 
DISCUSSION 
MicroRNAs have huge potential as biomarkers for malignant as well as benign 
conditions. Multiple studies have shown their discriminatory ability between health and disease.  
We tested the potential role of miRNAs as biomarkers for BE and esophageal adenocarcinoma, a 
cancer that has increased by 6-fold over the past decade and has a 5 year survival of ~20%.  The 
current diagnostic gold standard, upper endoscopy, is neither cost effective nor widely applicable 
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to detect the entire population at risk. Our study is unique because we focused on the miRNAs 
concentrated within serum exosomes. Circulating miRNAs are stable in two forms, one 
concentrated in membrane bound vesicles called exosomes and the other as protein bound 
complexes. Majority of work on the diagnostic potential of miRNAs did not discriminate 
between the two compartments that could have added to the variability of the signature and even 
lead to the dilution of the signature. We hypothesized that serum exosomal miRNA could be 
used as disease-specific diagnostic biomarkers because changes in their expression is influenced 
by the presence or absence of BE and cancer. Here, we compared exosomal miRNA profiles to 
determine a diagnostic signature for BE and EAC in patients with GERD. Our promising 
findings suggest that our signature has the potential to be developed into novel clinical assays for 
the diagnosis of BE and EAC.  
The field of exosomes in bodily fluids is rapidly evolving[40]. There are commercially 
available kits that can isolate serum exosomal miRNAs. The current literature contains evidence 
for positive[59] and negative results with these simple to use assays [40]. It appears that these 
commercial isolation kits may not select for exosomes exclusively and precipitate membrane-
free macromolecular aggregates and other types of membrane bound vesicles[40]. 
Ultracentrifugation is the gold standard for isolation of serum exosomes and was used in this 
proposal for comprehensive identification of novel serum exosomal miRNAs in BE and cancer.  
The current study is one of the first studies to examine the role of serum miRNAs for BE 
and cancer diagnosis. A recent Dutch study presented only in abstract form explored 
differentially expressed miRNA in plasma and found miRNAs -382, -133, -136, -194, and -451 
to be different between GERD, BE and EAC [60]. These miRNAs were absent from our PAM 
signatures. There were some differences between the Dutch study and our study. We specifically 
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focused on the miRNAs expressed in exosomes. We used next generation sequencing unlike 
miRNA microarray used in the Dutch study. Next generation sequencing is the gold standard for 
high-throughput miRNA analysis [61].When we compare our results of pairwise comparisons 
from EdgeR, there were some similarities. MicroRNA -451 was significant in BE vs. EAC and 
GERD vs. EAC comparisons. MicroRNA-194 was significant in GERD vs. BE and BE vs. EAC 
comparisons and microRNA-133 was significant BE vs. EAC comparisons. Although the 
purpose of this study was strictly to explore miRNAs as diagnostic biomarkers, it is possible that 
several of the discovered miRNAs may play a role in BE carcinogenesis. The IPA analysis 
suggested that several of the genes regulated by the identified miRNAs map to pathways 
associated with cancer development and inflammatory cascades. These three miRNA have been 
associated with gastrointestinal tumors with microRNA-133 with a possible tumor suppressive 
role. 
Our study has some limitations. Multiple physiological factors can affect serum exosomal 
miRNA content. Since blood is a complex mixture of biomolecules and cells, it is likely that some 
miRNA signals are from the cells other than esophageal. It is possible that serum miRNAs are 
markers for systemic process that predispose to BE. Irrespective of origin, the purpose of the serum 
miRNA evaluation in BE is to develop novel biomarkers. If the BE serum miRNA signature 
successfully fulfills the primary purpose of disease classification, then it will have clinical utility 
[62]. This study included 24 subjects for the high-throughput analysis. The sample sizes were 
relatively small because of cost constraints. We applied a sound statistical methodology for data 
analysis and discovered several potential candidates.  Future studies should include larger numbers 
to validate our results. We evaluated exosomal miRNAs. It is possible that non-exosomal miRNAs 
may carry diagnostic information. We have stored the non-exosomal supernatant and will be able 
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to test them if, upon validation, the exosomal signatures are not accurate. The primary control 
group in this study was participants with GERD instead of healthy controls. This is appropriate 
because GERD patients are the recommended population to undergo screening and are at the 
highest risk for BE and EAC, hence, they are logical controls for this type of investigation. 
Clinically, the accuracy and efficacy of the serum exosomal miRNA signature to diagnose BE will 
depend on the pre-test probability of disease that would be highest in the GERD population. An 
ideal disease signature should be able to differentiate among the stages of BE progression to stage 
4 cancer. However, we included BE patients with the extreme phenotypes of “no dysplasia” and 
“cancer” to maintain homogeneity for this preliminary work.  
 
This study has several strengths. Both clinical and laboratory protocols were strictly 
adhered to ensure the reproducibility and consistency of the results. Many recent studies have 
conducted similar research with the use of microarrays. However we feel the use of sequencing 
in our study gives us a more comprehensive picture of the possible differences in serum 
exosomal miRNA content. Additionally, with the information obtained from NGS we have the 
opportunity to discover unknown miRNAs. In this study, we focused our efforts on a minimally 
invasive blood-based diagnosis strategy, a significant improvement over conventional tissue 
based diagnosis. 
Two different methods, EdgeR and PAM were used for analysis of the miRNA profiles 
between GERD, BE and EAC. EdgeR is a tool that is intended to calculate the statistical 
probability of differentially expressed miRNAs between groups. It can also control for false 
discovery rates. However, it does not provide any information on the ability of patterns of gene 
expression in disease classification. PAM is able to classify samples based on the gene 
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expression data and also estimates prediction error based on cross validation. The output includes 
a list of genes that are characteristic of each disease category i.e. GERD, BE and EAC. The 
overall goal of the PAM algorithm is to find the smallest set of miRNAs that can accurately 
classify the samples. Its efficiency at identifying the smallest number of miRNAs that contribute 
the most to the classification makes this method ideal for creating a diagnostic signature. 
Concordance in miRNA analysis from both EdgeR and PAM suggest our signature is robust and 
discriminatory for the target conditions. Based on the overall goal and results, we will pursue the 
classifier signature generated by the PAM algorithm.  
Investigations in the immediate future will need to be conducted to validate the miRNA 
signature with alternative methods such as qRT-PCR. Subsequently, the signature need to be 
validated in independent cohorts. The development of a novel blood-based assay, independent of 
endoscopy, will provide a range of medical professionals the ability to accurately suspect BE and 
cancer with minimal effort with more convenience for the patient. The ability to timely diagnose 
BE and EAC has the potential to improve patient outcomes and survival.  
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APPENDIX 
Appendix A: GERD vs BE-Significant miRNAs by ascending p-value  
Gene ID logFC Fold 
Change 
PValue FDR Average Read 
Count for 
GERD 
Average 
Read 
Count for 
BE 
hsa-miR-197-3phsa-mir-197 -1.82 0.28 4.81E-04 1.70E-01 35 124 
hsa-miR-411-5phsa-mir-411 1.73 3.32 2.12E-03 3.25E-01 10 3 
hsa-miR-208b-3phsa-mir-
208b 
2.75 6.72 3.81E-03 3.25E-01 17 3 
hsa-miR-194-5phsa-mir-194-2 1.55 2.92 4.03E-03 3.25E-01 139 48 
hsa-miR-194-5phsa-mir-194-1 1.53 2.89 4.60E-03 3.25E-01 127 44 
hsa-miR-378a-3phsa-mir-378a 1.19 2.27 1.01E-02 4.92E-01 2769 1217 
hsa-miR-4792hsa-mir-4792 2.32 4.98 1.14E-02 4.92E-01 13 2 
hsa-miR-181d-5phsa-mir-
181d 
-1.15 0.45 1.61E-02 4.92E-01 3 8 
hsa-miR-941hsa-mir-941-1 -0.88 0.54 1.78E-02 4.92E-01 54 99 
hsa-miR-941hsa-mir-941-5 -0.88 0.54 1.80E-02 4.92E-01 54 99 
hsa-miR-941hsa-mir-941-4 -0.88 0.54 1.81E-02 4.92E-01 54 99 
hsa-miR-941hsa-mir-941-2 -0.88 0.54 1.81E-02 4.92E-01 54 99 
hsa-miR-941hsa-mir-941-3 -0.88 0.54 1.81E-02 4.92E-01 54 99 
hsa-miR-4732-3phsa-mir-
4732 
-0.80 0.58 2.08E-02 5.24E-01 77 133 
hsa-miR-410-3phsa-mir-410 0.92 1.90 3.15E-02 7.40E-01 28 15 
hsa-miR-30a-3phsa-mir-30a 1.05 2.07 3.67E-02 8.11E-01 26 12 
hsa-miR-125b-2-3phsa-mir-
125b-2 
1.28 2.42 4.23E-02 8.78E-01 62 26 
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Appendix B: GERD vs EAC-Significant miRNAs by ascending p-value 
Gene ID logFC Fold 
Change 
PValue FDR Average Read 
Count for 
GERD 
Average 
Read Count 
for EAC 
hsa-miR-148b-3phsa-mir-148b -1.39 0.38 3.90E-05 1.38E-02 124 326 
hsa-miR-122-5phsa-mir-122 2.99 7.92 1.82E-04 2.54E-02 214 27 
hsa-let-7b-5phsa-let-7b 1.31 2.48 2.53E-04 2.54E-02 555 223 
hsa-miR-191-5phsa-mir-191 -1.29 0.41 2.88E-04 2.54E-02 2073 5077 
hsa-miR-151bhsa-mir-151a -1.11 0.46 5.43E-04 3.22E-02 188 407 
hsa-miR-151a-5phsa-mir-151a -1.11 0.46 5.48E-04 3.22E-02 679 1132 
hsa-miR-127-3phsa-mir-127 -1.59 0.33 7.40E-04 3.73E-02 43 128 
hsa-miR-486-3phsa-mir-486-2 1.20 2.30 1.76E-03 7.70E-02 690 300 
hsa-miR-486-3phsa-mir-486-1 1.19 2.28 1.96E-03 7.70E-02 700 307 
hsa-miR-29c-3phsa-mir-29c 1.13 2.19 2.42E-03 8.56E-02 225 102 
hsa-miR-99b-5phsa-mir-99b -1.24 0.42 2.77E-03 8.89E-02 86 204 
hsa-miR-181a-5phsa-mir-181a-2 -0.98 0.51 3.70E-03 1.00E-01 2409 4760 
hsa-miR-181a-5phsa-mir-181a-1 -0.98 0.51 3.70E-03 1.00E-01 14 26 
hsa-miR-222-3phsa-mir-222 -1.06 0.48 4.12E-03 1.04E-01 245 513 
hsa-miR-16-5phsa-mir-16-1 0.85 1.81 5.46E-03 1.10E-01 26873 14867 
hsa-miR-150-3phsa-mir-150 -2.06 0.24 5.47E-03 1.10E-01 26 108 
hsa-miR-16-5phsa-mir-16-2 0.85 1.81 5.50E-03 1.10E-01 551 353 
hsa-miR-26a-5phsa-mir-26a-1 -1.01 0.49 6.34E-03 1.10E-01 2494 5039 
hsa-miR-26a-5phsa-mir-26a-2 -1.01 0.50 6.43E-03 1.10E-01 2509 5066 
hsa-miR-574-5phsa-mir-574 1.84 3.58 6.46E-03 1.10E-01 8 2 
hsa-miR-10b-5phsa-mir-10b -1.41 0.38 6.60E-03 1.10E-01 12951 34304 
hsa-let-7c-5phsa-let-7c 1.27 2.41 6.88E-03 1.10E-01 94 39 
hsa-miR-744-5phsa-mir-744 -0.85 0.56 7.31E-03 1.12E-01 130 233 
hsa-miR-409-3phsa-mir-409 -1.30 0.41 8.52E-03 1.21E-01 49 120 
hsa-miR-19a-3phsa-mir-19a 1.06 2.09 9.14E-03 1.21E-01 203 97 
hsa-miR-184hsa-mir-184 -1.56 0.34 9.47E-03 1.21E-01 15 46 
hsa-miR-182-5phsa-mir-182 -1.26 0.42 9.53E-03 1.21E-01 1443 3453 
hsa-miR-29a-3phsa-mir-29a 1.14 2.21 9.61E-03 1.21E-01 491 222 
hsa-miR-378a-3phsa-mir-378a 1.19 2.27 1.01E-02 1.23E-01 2769 1217 
hsa-miR-181b-5phsa-mir-181b-2 -0.75 0.60 1.09E-02 1.28E-01 141 237 
hsa-miR-181b-5phsa-mir-181b-1 -0.75 0.60 1.13E-02 1.28E-01 140 234 
hsa-let-7a-3phsa-let-7a-3 1.10 2.14 1.19E-02 1.31E-01 21 10 
hsa-miR-330-3phsa-mir-330 -1.05 0.48 1.24E-02 1.33E-01 6 13 
hsa-let-7a-3phsa-let-7a-1 1.08 2.12 1.31E-02 1.36E-01 21 10 
hsa-miR-221-5phsa-mir-221 -1.72 0.30 1.37E-02 1.38E-01 3 11 
hsa-miR-301a-3phsa-mir-301a -0.87 0.55 1.46E-02 1.42E-01 77 141 
hsa-miR-32-5phsa-mir-32 0.95 1.93 1.50E-02 1.42E-01 724 1556 
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hsa-miR-378ihsa-mir-378i 1.22 2.33 1.53E-02 1.42E-01 39 16 
hsa-miR-671-3phsa-mir-671 -1.07 0.48 1.68E-02 1.52E-01 10 20 
hsa-miR-185-5phsa-mir-185 1.37 2.58 1.98E-02 1.61E-01 8 3 
hsa-miR-589-5phsa-mir-589 -1.25 0.42 2.06E-02 1.61E-01 50 118 
hsa-miR-584-5phsa-mir-584 -0.75 0.59 2.10E-02 1.61E-01 143 241 
hsa-miR-125a-5phsa-mir-125a -0.80 0.57 2.14E-02 1.61E-01 110 192 
hsa-miR-374a-3phsa-mir-374a -1.16 0.45 2.19E-02 1.61E-01 10 23 
hsa-miR-423-3phsa-mir-423 -0.72 0.61 2.24E-02 1.61E-01 880 1449 
hsa-miR-142-5phsa-mir-142 0.75 1.68 2.25E-02 1.61E-01 76 130 
hsa-miR-451ahsa-mir-451a 0.79 1.72 2.25E-02 1.61E-01 17275 10018 
hsa-miR-335-3phsa-mir-335 -0.99 0.51 2.30E-02 1.61E-01 9 19 
hsa-miR-199a-3phsa-mir-199a-1 0.71 1.64 2.46E-02 1.61E-01 13 24 
hsa-miR-199b-3phsa-mir-199a-1 0.71 1.64 2.46E-02 1.61E-01 529 328 
hsa-miR-130a-3phsa-mir-130a 0.72 1.65 2.46E-02 1.61E-01 609 369 
hsa-miR-199a-3phsa-mir-199b 0.71 1.64 2.47E-02 1.61E-01 527 321 
hsa-miR-199b-3phsa-mir-199b 0.71 1.64 2.49E-02 1.61E-01 527 321 
hsa-miR-19b-3phsa-mir-19b-1 0.95 1.93 2.49E-02 1.61E-01 592 306 
hsa-miR-19b-3phsa-mir-19b-2 0.95 1.93 2.51E-02 1.61E-01 593 307 
hsa-miR-4732-5phsa-mir-4732 1.06 2.09 2.61E-02 1.64E-01 29 13 
hsa-miR-342-3phsa-mir-342 0.93 1.90 2.65E-02 1.64E-01 162 85 
hsa-miR-199b-3phsa-mir-199a-2 0.69 1.61 2.95E-02 1.78E-01 527 321 
hsa-miR-199a-3phsa-mir-199a-2 0.69 1.61 2.97E-02 1.78E-01 527 321 
hsa-miR-208b-3phsa-mir-208b 1.95 3.85 3.05E-02 1.79E-01 17 4 
hsa-miR-181a-3phsa-mir-181a-1 -0.82 0.57 3.20E-02 1.79E-01 2409 4760 
hsa-miR-181d-5phsa-mir-181d -1.01 0.50 3.25E-02 1.79E-01 3 7 
hsa-miR-142-3phsa-mir-142 -0.77 0.59 3.30E-02 1.79E-01 5262 3128 
hsa-miR-151a-3phsa-mir-151a -0.74 0.60 3.35E-02 1.79E-01 189 410 
hsa-miR-548ar-5phsa-mir-548ar 0.85 1.81 3.37E-02 1.79E-01 22 12 
hsa-miR-101-3phsa-mir-101-1 0.67 1.60 3.41E-02 1.79E-01 2465 1544 
hsa-miR-101-3phsa-mir-101-2 0.67 1.59 3.51E-02 1.79E-01 2530 1589 
hsa-miR-320bhsa-mir-320b-1 -1.11 0.46 3.56E-02 1.79E-01 86 44 
hsa-miR-532-5phsa-mir-532 0.62 1.54 3.57E-02 1.79E-01 221 143 
hsa-miR-320bhsa-mir-320b-2 -1.10 0.47 3.59E-02 1.79E-01 721 1552 
hsa-miR-199a-5phsa-mir-199a-1 -0.83 0.56 3.63E-02 1.79E-01 13 24 
hsa-miR-199a-5phsa-mir-199a-2 -0.83 0.56 3.65E-02 1.79E-01 529 328 
hsa-miR-30b-5phsa-mir-30b -0.89 0.54 3.77E-02 1.80E-01 103 191 
hsa-miR-210-3phsa-mir-210 0.92 1.89 3.80E-02 1.80E-01 112 59 
hsa-miR-411-5phsa-mir-411 -1.07 0.47 3.83E-02 1.80E-01 10 22 
hsa-miR-15a-5phsa-mir-15a 0.79 1.73 3.91E-02 1.82E-01 2629 1518 
hsa-miR-885-5phsa-mir-885 1.73 3.33 4.55E-02 2.08E-01 53 16 
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hsa-miR-16-2-3phsa-mir-16-2 0.64 1.56 4.68E-02 2.12E-01 26871 14863 
hsa-miR-3605-5phsa-mir-3605 1.03 2.04 4.90E-02 2.19E-01 8 4 
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Appendix C : BE vs EAC-Significant miRNAs by ascending p-value 
Gene ID logFC Fold 
Change 
PValue FDR Average Read 
Count for BE 
Average Read 
Count for 
EAC 
hsa-let-7b-5phsa-let-7b 1.79 3.46 7.97E-07 2.06E-04 773 223 
hsa-miR-411-5phsa-mir-411 -2.81 0.14 1.17E-06 2.06E-04 3 22 
hsa-miR-127-3phsa-mir-127 -2.04 0.24 2.24E-05 2.34E-03 31 128 
hsa-miR-197-3phsa-mir-197 2.23 4.69 2.65E-05 2.34E-03 124 26 
hsa-miR-99b-5phsa-mir-99b -1.70 0.31 5.63E-05 3.09E-03 63 204 
hsa-miR-151bhsa-mir-151a -1.30 0.41 5.96E-05 3.09E-03 166 407 
hsa-miR-10b-5phsa-mir-10b -2.11 0.23 6.82E-05 3.09E-03 7972 34304 
hsa-miR-148b-3phsa-mir-148b -1.34 0.40 7.79E-05 3.09E-03 130 326 
hsa-miR-151a-5phsa-mir-151a -1.28 0.41 7.87E-05 3.09E-03 169 410 
hsa-miR-181a-5phsa-mir-181a-2 -1.30 0.41 1.41E-04 4.52E-03 1936 4760 
hsa-miR-181a-5phsa-mir-181a-1 -1.30 0.41 1.41E-04 4.52E-03 1936 4760 
hsa-miR-181b-5phsa-mir-181b-1 -1.12 0.46 1.78E-04 5.25E-03 108 234 
hsa-miR-486-3phsa-mir-486-2 1.43 2.69 2.23E-04 5.83E-03 807 300 
hsa-miR-181b-5phsa-mir-181b-2 -1.09 0.47 2.35E-04 5.83E-03 111 237 
hsa-miR-486-3phsa-mir-486-1 1.42 2.67 2.48E-04 5.83E-03 819 307 
hsa-miR-181a-3phsa-mir-181a-1 -1.42 0.37 3.26E-04 7.20E-03 9 26 
hsa-miR-10a-5phsa-mir-10a -1.84 0.28 4.33E-04 8.99E-03 2879 10305 
hsa-miR-410-3phsa-mir-410 -1.50 0.35 5.41E-04 1.06E-02 15 41 
hsa-miR-16-5phsa-mir-16-1 1.01 2.02 1.01E-03 1.79E-02 30015 14863 
hsa-miR-16-5phsa-mir-16-2 1.01 2.02 1.02E-03 1.79E-02 30019 14867 
hsa-miR-451ahsa-mir-451a 1.13 2.19 1.14E-03 1.84E-02 21898 10018 
hsa-miR-191-5phsa-mir-191 -1.16 0.45 1.14E-03 1.84E-02 2279 5077 
hsa-miR-4732-5phsa-mir-4732 1.56 2.95 1.32E-03 2.03E-02 41 13 
hsa-miR-19a-3phsa-mir-19a 1.31 2.48 1.46E-03 2.15E-02 240 97 
hsa-miR-320bhsa-mir-320b-1 -1.65 0.32 2.03E-03 2.87E-02 496 1552 
hsa-miR-320bhsa-mir-320b-2 -1.63 0.32 2.20E-03 2.99E-02 502 1556 
hsa-miR-576-5phsa-mir-576 1.18 2.26 2.52E-03 3.29E-02 31 15 
hsa-miR-126-5phsa-mir-126 -0.98 0.51 2.70E-03 3.40E-02 2184 4310 
hsa-miR-184hsa-mir-184 -1.83 0.28 2.86E-03 3.48E-02 13 46 
hsa-miR-122-5phsa-mir-122 2.28 4.86 3.29E-03 3.62E-02 131 27 
hsa-miR-5010-5phsa-mir-5010 1.36 2.56 3.31E-03 3.62E-02 25 10 
hsa-miR-550a-3phsa-mir-550a-2 1.32 2.49 3.35E-03 3.62E-02 21 9 
hsa-miR-550a-3phsa-mir-550a-1 1.32 2.49 3.38E-03 3.62E-02 21 9 
hsa-miR-550a-3phsa-mir-550a-3 1.32 2.49 3.50E-03 3.64E-02 21 9 
hsa-miR-374a-3phsa-mir-374a -1.53 0.35 3.88E-03 3.76E-02 8 23 
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hsa-miR-19b-3phsa-mir-19b-1 1.23 2.34 3.95E-03 3.76E-02 717 306 
hsa-miR-19b-3phsa-mir-19b-2 1.23 2.34 3.96E-03 3.76E-02 719 307 
hsa-miR-4732-3phsa-mir-4732 1.00 2.00 4.05E-03 3.76E-02 133 67 
hsa-miR-222-3phsa-mir-222 -1.05 0.48 4.60E-03 4.07E-02 247 513 
hsa-miR-671-3phsa-mir-671 -1.31 0.40 4.61E-03 4.07E-02 8 20 
hsa-miR-26a-5phsa-mir-26a-1 -1.04 0.48 5.01E-03 4.31E-02 2444 5039 
hsa-miR-26a-5phsa-mir-26a-2 -1.04 0.49 5.19E-03 4.36E-02 2463 5066 
hsa-miR-629-5phsa-mir-629 -1.63 0.32 6.14E-03 5.04E-02 4 13 
hsa-miR-150-3phsa-mir-150 -2.03 0.25 6.40E-03 5.14E-02 26 108 
hsa-miR-133a-3phsa-mir-133a-1 -1.45 0.37 8.56E-03 6.60E-02 25 69 
hsa-miR-133a-3phsa-mir-133a-2 -1.45 0.37 8.61E-03 6.60E-02 25 69 
hsa-miR-30a-3phsa-mir-30a -1.31 0.40 9.85E-03 7.40E-02 12 31 
hsa-miR-151a-3phsa-mir-151a -0.88 0.54 1.12E-02 8.22E-02 613 1132 
hsa-miR-16-2-3phsa-mir-16-2 0.82 1.76 1.18E-02 8.46E-02 621 353 
hsa-miR-223-3phsa-mir-223 1.17 2.25 1.21E-02 8.46E-02 328 146 
hsa-miR-409-3phsa-mir-409 -1.24 0.42 1.22E-02 8.46E-02 51 120 
hsa-miR-150-5phsa-mir-150 1.35 2.55 1.35E-02 9.19E-02 2081 818 
hsa-miR-342-3phsa-mir-342 1.03 2.04 1.42E-02 9.44E-02 174 85 
hsa-miR-589-5phsa-mir-589 -1.32 0.40 1.50E-02 9.78E-02 47 118 
hsa-miR-194-5phsa-mir-194-1 -1.27 0.41 1.80E-02 1.16E-01 44 106 
hsa-miR-194-5phsa-mir-194-2 -1.25 0.42 1.93E-02 1.20E-01 48 113 
hsa-miR-106b-5phsa-mir-106b 0.88 1.84 1.97E-02 1.20E-01 217 118 
hsa-miR-21-3phsa-mir-21 -1.28 0.41 1.98E-02 1.20E-01 131 318 
hsa-miR-320chsa-mir-320c-1 -1.36 0.39 2.11E-02 1.26E-01 14 36 
hsa-miR-320chsa-mir-320c-2 -1.54 0.34 2.29E-02 1.34E-01 7 19 
hsa-miR-32-5phsa-mir-32 0.89 1.85 2.31E-02 1.34E-01 82 44 
hsa-miR-423-3phsa-mir-423 -0.71 0.61 2.35E-02 1.34E-01 884 1449 
hsa-miR-15a-5phsa-mir-15a 0.86 1.82 2.46E-02 1.38E-01 2764 1518 
hsa-miR-769-5phsa-mir-769 0.93 1.90 2.50E-02 1.38E-01 63 34 
hsa-miR-1180-3phsa-mir-1180 1.02 2.02 2.75E-02 1.49E-01 7 4 
hsa-miR-93-3phsa-mir-93 0.87 1.82 3.14E-02 1.68E-01 15 8 
hsa-miR-3173-5phsa-mir-3173 1.12 2.17 3.41E-02 1.78E-01 8 3 
hsa-miR-361-3phsa-mir-361 0.77 1.70 3.43E-02 1.78E-01 50 29 
hsa-miR-143-3phsa-mir-143 1.01 2.02 3.63E-02 1.83E-01 1955 970 
hsa-miR-24-3phsa-mir-24-2 -1.01 0.50 3.71E-02 1.83E-01 62 124 
hsa-miR-24-3phsa-mir-24-1 -1.00 0.50 3.74E-02 1.83E-01 62 124 
hsa-miR-425-5phsa-mir-425 0.61 1.53 3.82E-02 1.83E-01 1042 680 
hsa-miR-10a-3phsa-mir-10a -1.26 0.42 3.82E-02 1.83E-01 3 7 
hsa-miR-20a-5phsa-mir-20a 0.67 1.60 3.84E-02 1.83E-01 149 94 
hsa-miR-142-5phsa-mir-142 0.68 1.60 3.95E-02 1.83E-01 4999 3128 
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hsa-miR-330-3phsa-mir-330 -0.88 0.54 3.99E-02 1.83E-01 7 13 
hsa-miR-501-3phsa-mir-501 -0.95 0.52 4.00E-02 1.83E-01 23 44 
hsa-miR-34a-5phsa-mir-34a 1.40 2.65 4.04E-02 1.83E-01 13 5 
hsa-miR-92a-3phsa-mir-92a-2 0.67 1.59 4.12E-02 1.84E-01 92518 58200 
hsa-miR-185-5phsa-mir-185 1.20 2.30 4.27E-02 1.88E-01 6 3 
hsa-miR-30b-5phsa-mir-30b -0.87 0.55 4.35E-02 1.89E-01 105 191 
hsa-miR-144-5phsa-mir-144 -0.94 0.52 4.45E-02 1.91E-01 915 1752 
hsa-miR-381-3phsa-mir-381 -0.99 0.50 4.53E-02 1.93E-01 11 21 
hsa-miR-942-5phsa-mir-942 0.67 1.60 4.76E-02 1.99E-01 27 16 
hsa-miR-92a-3phsa-mir-92a-1 0.63 1.54 4.78E-02 1.99E-01 95502 61833 
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Appendix D: EdgeR Unsupervised clustering and heat map. 
 
Columns represent patient samples and rows represent the significant genes from EdgeR analysis 
(FDR<0.05). Scale bar indicates expression signal where yellow denotes genes with relative increased 
expression while blue denotes genes with relative decreased expression. 
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Appendix: E: Top 15 disease and functions from IPA on each pairwise comparison  
 
 
(A) GERD vs BE (B) GERD vs EAC (C) BE vs EAC 
A. 
B. 
C. 
